Streetwise Reports' Article Archives — December 2020 back to current month (29)
California Biotech Advances Two COVID-19 Products (12/30/2020)
Recent news concerning Sorrento Therapeutics' SARS-CoV-2 virus test and antibodies is discussed in a Dawson James Securities report.
The next steps for advancing Oramed Pharmaceuticals' oral therapy candidates are provided in an H.C. Wainwright & Co. report.
Shares of DermTech Inc. climbed to a new 52-week high after the company reported it has received positive medical coverage by Geisinger Health System for its pigmented lesion assay, a non-invasive test for detecting melanoma.
Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication.
Shares of Myovant Sciences established a new 52-week high after the company entered into an agreement with Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) for advanced prostate cancer and relugolix combination tablet for women's health in the U.S. and Canada.
The factors that set Athersys' stem cell product MultiStem apart from a competitor's therapeutic are provided in a Dawson James Securities report.
Supernus Pharmaceuticals shares reached a new 52-week high price after the company reported positive results from its Phase 3 Study of SPN-812 for treating adults with attention deficit hyperactivity disorder.
Revive Therapeutics reported it has submitted a non-binding letter of intent to acquire 100% of PharmaTher Inc.'s psilocybin program.
Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial.
Shares of Agios Pharmaceuticals traded 30% higher after the company reported that it has agreed to sell its oncology research business to France's Servier Group in a transaction valued up to US$2 billion in cash plus future royalties.
Avivagen Inc. reported FY/20 audited financial results that included a 20.5% increase in YoY revenue.
Shares of BioTelemetry Inc. rise 16.5% to a new 52-week high after Royal Philips agreed to acquire the company for US$2.8 billion, or US$72.00 per share in an all cash transaction.
Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme.
Extraordinary achievement promises to help turn the tide against the COVID 19 pandemic, Knox Henderson writes.
The transaction details and expected impact on Aytu BioScience's balance sheet are provided in a Ladenburg Thalmann report.
Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report.
Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators.
Shares of Prevail Therapeutics reached a new 52-week high after the company reported it has signed a definitive agreement to be acquired by Ely Lilly in a deal valued up to $1.04 billion.
Shares of Alexion Pharmaceuticals reached a new 52-week high after the company reported it entered into a definitive agreement to be acquired by AstraZeneca in a combination cash and stock deal valued at US$39 billion.
Shares of NantHealth Inc. climbed to a new 52-week high after the healthcare IT company presented what it called significant treatment insights at the 2020 San Antonio Breast Cancer Symposium.
Shares of TG Therapeutics reached a new 52-week high after the company released positive topline results from the Phase 3 ULTIMATE I & II Studies of ublituximab as a monotherapy for treating relapsing multiple sclerosis.
Shares of Grenwich Lifesciences soared more than 2,300% to a new 52-week high after the company gave a poster presentation of 5-year data for the Phase 2b GP2 clinical trial that showed 0% recurrence of breast cancer.
Curis Inc. shares reached a new 52-week high after the cancer therapeutics developer reported positive preliminary data from two Phase 1 studies, one treating relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes and another treating relapsed or refractory non-Hodgkin's lymphoma.
Fate Therapeutics shares set a new 52-week high after the firm reported positive interim data from its Phase 1 Study of FT516 in combination with rituximab for B-cell lymphoma. In a separate Phase 1 study, the company presented the results of a patient treated with natural killer cell cancer immunotherapy FT596 in refractory diffuse large B-cell lymphoma.
Recent trial results, a timeline to the launch of Quotient's system and the reasons the debut should be successful are discussed in a Cowen report.
BioCryst Pharmaceuticals shares traded 17% higher after the company reported that the FDA approved its once-daily oral therapy ORLADEYO™ (berotralstat) for prevention of attacks in hereditary angioedema patients.
Shares of Oramed Pharmaceuticals traded higher after the company announced that it has initiated a Phase 2 NASH trial of oral insulin as a complementary agent or alternative to insulin injections.
The rationale behind OncoSec Medical using this system is discussed in a Dawson James report.
Patterson Companies shares traded higher and set a new 52-week high after the firm reported Q2/21 financial results which included a 12.1% YoY increase in dental equipment and consumable supply sales.
|"We are initiating research coverage on VIV with an Outperform rating."|